Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / Antengene ATG-201 IND Approval China
Tech IND approval

Antengene ATG-201 IND Approval China

Analysis based on 8 articles · First reported Jun 10, 2026 · Last updated Jun 10, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The IND approval for ATG-201 in China is a positive development for Antengene, indicating progress in its pipeline and expansion into the autoimmune disease market. This could lead to increased investor confidence and potential future revenue streams for Antengene and EITC, who holds the exclusive license.

Biotechnology Pharmaceuticals
Event Summary

Antengene Corporation Limited received Investigational New Drug (IND) approval from China's China — National Medical Products Administration (NMPA) for its Phase I ATTRACT study of ATG-201. ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed to treat B cell related autoimmune diseases. This approval marks Antengene's strategic expansion into autoimmune diseases, moving beyond its traditional focus on oncology and hematology. Professor Li Zhanguo from Peking University People s Hospital will lead the Phase I clinical study in China, which aims to evaluate the safety, tolerability, and preliminary efficacy of ATG-201. Antengene also plans to initiate clinical development in Australia. Furthermore, Antengene has granted EITC a worldwide exclusive license to develop, manufacture, and commercialize ATG-201 after the initial Phase I trials.

Key Actions
100 China — National Medical Products Administration approved IND application Antengene
90 Antengene will conduct trials ATG-201
80 Antengene expanded strategic focus
70 Antengene entered licensing agreement EITC
Entities Involved
priv
Antengene
Antengene received IND approval for ATG-201 in China, marking a significant expansion into autoimmune diseases and potentially increasing its market value and strategic importance. Antengene will conduct initial clinical trials in China and Australia before transferring development to EITC.
Importance 100 Sentiment 70
oth
ATG-201
ATG-201, a CD19/CD3 bispecific T-cell engager antibody, received IND approval for Phase I clinical trials in China for B cell related autoimmune diseases. This approval is a crucial step in its development and potential commercialization.
Importance 90 Sentiment 60
govactor
China — National Medical Products Administration
The China — National Medical Products Administration approved the IND application for ATG-201, enabling Antengene to proceed with Phase I clinical trials in China.
Importance 80 Sentiment 0
cnt
China
China's China — National Medical Products Administration approved the IND application for ATG-201, facilitating the initiation of Phase I clinical trials within the country.
Importance 70 Sentiment 0
stock
EITC
EITC has entered into an agreement with Antengene, granting EITC a worldwide exclusive license to develop, manufacture, and commercialize ATG-201 after Antengene completes the initial Phase I trials.
Importance 60 Sentiment 50
per
Li Zhanguo
Professor Li Zhanguo will lead the Phase I ATTRACT study of ATG-201 as the principal investigator, overseeing its safety, tolerability, and preliminary efficacy evaluation.
Importance 50 Sentiment 0
cnt
Australia
Antengene is preparing for the clinical development of ATG-201 in Australia, indicating future expansion of the drug's trials beyond China.
Importance 40 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.